Haitong International: BeiGene (06160.HK) The sales volume of zebutinib in the American and European markets exceeded expectations and maintained an "outperform the market" rating.

According to the Wisdom Financial News APP, Haitong International released a research report stating that considering the strong volume of Zebutinib, a drug by BeiGene (06160.HK), in the US and European markets, the bank has raised its revenue forecast for 2025-2027 to $5.3 billion/ $6.4 billion/ $7.1 billion, with a corresponding compound annual growth rate of 23%. The bank also raised BeiGene's net profit attributable to shareholders to $360 million/ $660 million/ $1.05 billion, reflecting better-than-expected growth in sales and research and development expenses. Based on a weighted average cost of capital of 9% and a perpetual growth rate of 4%, the group's target price is HK$213.1, maintaining a "outperform" rating in the market.